Table 1.
Current studies using CRISPR-based screens in hPSC-derived cells
Year | Stem cell type | Differentiated cell type | CRISPR type | Screening strategy | Phenotype | Library size | Reference |
---|---|---|---|---|---|---|---|
2018 | hiPSC | hepatocyte-like cell | CRISPRn | FACS | hepatocytic differentiation | genome-wide | Li et al.15 |
2019 | hiPSC & hESC | neural progenitor | CRISPRn | survival | cytotoxicity of Zika virus infection | genome-wide | Li et al.16 |
2019 | hiPSC | glutamatergic neuron | CRISPRi | survival | neuronal survival | CRISPRi-v2 H1 library (∼2,000 genes encoding kinases, phosphatases, and drug targets) | Tian et al.17 |
single-cell transcriptomics | transcriptome changes in response to gene knockdown | 27 hit genes | |||||
imaging | neurite morphology | 23 hit genes | |||||
2020 | hESC | cerebral organoid | CRISPRn | proliferation | cerebral organoid growth | 172 microcephaly candidate genes | Esk et al.18 |
2020 | hESC | cardiac mesoderm and progenitor | CRISPRn | FACS | formation of cardiac mesoderm and progenitors (MSP1 and ISL1 staining) | ∼6,000 genes | Xu et al.19 |
2021 | hiPSC | glutamatergic neuron | CRISPRi/a | survival | neuronal survival under normal and oxidative stress conditions | genome-wide (hCRISPRi/a-v2 library) | Tian et al.20 |
FACS | levels of ROS and lipid peroxidation | genome-wide & a focused library against 730 hit genes | |||||
single-cell transcriptomics | transcriptome changes in response to gene knockdown | 184 hit genes for CRISPRi and 100 hit genes for CRISPRa | |||||
2021 | hiPSC | cardiomyocyte | CRISPRn | survival | doxorubicin-induced cardiotoxicity | genome-wide | Sapp et al.21 |
2022 | hiPSC | neural stem cell | CRISPRi | proliferation; FACS | cell proliferation during neuronal induction; neural differentiation (PAX6 staining) | genome-wide libraries against coding and lncRNA genes | Wu et al.22 |
single-cell transcriptomics screens | transcriptome changes in response to gene knockdown | 240 targets (120 coding genes and 120 lncRNA genes) | |||||
2022 | hiPSC | human subpallial organoid | CRISPRn | FACS | interneuron differentiation | 425 neurodevelopmental disorder related genes | Meng et al.23 |
human forebrain assembloid | interneuron migration | ||||||
2022 | hiPSC | cortical neuron | CRISPRn | survival | cytotoxicity of PR20 dipeptide repeats | kinome-wide (736 kinases) | Guo et al.24 |
2022 | hiPSC | astrocyte | CRISPRi | FACS | inflammatory reactivity of astrocytes (synaptosome phagocytosis; cell-surface VCAM1 levels) | human transcription factors and druggable genome (~4,000 targets) | Leng et al.25 |
single-cell transcriptomics | transcriptome changes in response to gene knockdown | 30 hit genes | |||||
2022 | hiPSC | microglia | CRISPRi/a | survival/proliferation | microglia survival and proliferation | CRISPRi-v2 H1 library (∼2,000 genes encoding kinases, phosphatases, and drug targets) | Dräger et al.26 |
FACS | microglia activation (CD38 staining) | ||||||
microglia phagocytosis of pHrodo-Red-labeled synaptosomes | |||||||
single-cell transcriptomics | transcriptome changes in response to gene knockdown | 39 hit genes | |||||
2022 | hiPSC | kidney organoid | CRISPRn | proliferation | kidney development and cell proliferation | genome-wide | Ungricht et al.27 |
This table summarizes current studies using CRISPR-based screens in hPSC-derived cells. CRISPRn, CRISPR knockout; CRISPRi, CRISPR interference; CRISPRa, CRISPR activation; hPSC, human pluripotent stem cell; hESC, human embryonic stem cell; hiPSC, human induced pluripotent stem cell; FACS, fluorescence-activated cell sorting.